Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMMBNASDAQ:MNOVNASDAQ:SAVANASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$1.37+1.5%$1.25$0.60▼$2.55$19.67M0.66215,487 shs57,188 shsMNOVMediciNova$1.47-3.3%$1.48$1.12▼$2.55$72.10M0.7538,675 shs2,356 shsSAVACassava Sciences$1.62+3.8%$1.96$1.15▼$42.20$78.26M-1.482.97 million shs725,177 shsSTROSutro Biopharma$1.07+1.9%$0.92$0.52▼$5.17$90.27M1.71.07 million shs1.62 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics+5.47%+12.50%+23.85%-33.82%+92.86%MNOVMediciNova-4.40%+1.33%+4.11%-25.85%+17.83%SAVACassava Sciences0.00%-6.02%+4.00%-34.45%-92.96%STROSutro Biopharma+20.04%+16.67%+61.39%-46.15%-69.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMMBChemomab Therapeutics3.5795 of 5 stars3.55.00.00.03.41.71.3MNOVMediciNova1.8838 of 5 stars3.53.00.00.02.10.80.0SAVACassava Sciences3.6313 of 5 stars3.32.00.04.71.60.01.3STROSutro Biopharma4.38 of 5 stars4.12.00.04.73.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics 3.00Buy$9.00556.93% UpsideMNOVMediciNova 3.00Buy$9.00512.24% UpsideSAVACassava Sciences 2.50Moderate Buy$54.503,264.20% UpsideSTROSutro Biopharma 2.22Hold$6.63519.16% UpsideCurrent Analyst Ratings BreakdownLatest CMMB, SAVA, MNOV, and STRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.004/9/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/25/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/17/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$12.00 ➝ $2.003/14/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.003/14/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/14/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/14/2025STROSutro BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/14/2025STROSutro BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$8.00 ➝ $2.003/14/2025STROSutro BiopharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Underperform$11.00 ➝ $1.003/4/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/AMNOVMediciNova$1M72.10N/AN/A$1.07 per share1.37SAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/ASTROSutro Biopharma$62.04M1.45N/AN/A$2.45 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$24.22M-$0.90N/AN/AN/AN/A-101.70%-76.18%5/8/2025 (Estimated)MNOVMediciNova-$8.56M-$0.23N/AN/AN/AN/A-19.66%-18.63%5/8/2025 (Estimated)SAVACassava Sciences-$97.22M-$1.45N/AN/AN/AN/A-88.05%-64.98%5/9/2025 (Estimated)STROSutro Biopharma-$106.79M-$3.02N/AN/AN/A-77.01%-101.89%-28.69%5/12/2025 (Estimated)Latest CMMB, SAVA, MNOV, and STRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025STROSutro Biopharma-$0.63N/AN/AN/A$11.61 millionN/A5/8/2025Q1 2025CMMBChemomab Therapeutics-$0.20N/AN/AN/AN/AN/A5/8/2025N/AMNOVMediciNova-$0.14N/AN/AN/AN/AN/A3/13/2025Q4 2024STROSutro Biopharma-$0.86-$2.96-$2.10-$0.89$10.44 million$14.00 million3/3/2025Q4 2024SAVACassava Sciences-$0.68-$0.57+$0.11-$0.57N/AN/A2/19/2025Q4 2024MNOVMediciNova-$0.06-$0.06N/A-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A4.574.57MNOVMediciNovaN/A13.8816.66SAVACassava SciencesN/A3.553.55STROSutro BiopharmaN/A3.093.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%MNOVMediciNova9.90%SAVACassava Sciences38.05%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%MNOVMediciNova14.90%SAVACassava Sciences9.00%STROSutro Biopharma5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics2014.36 million12.65 millionNot OptionableMNOVMediciNova1049.05 million41.74 millionOptionableSAVACassava Sciences3048.31 million43.78 millionOptionableSTROSutro Biopharma24084.36 million77.59 millionOptionableCMMB, SAVA, MNOV, and STRO HeadlinesRecent News About These CompaniesSutro Biopharma to Participate in Upcoming Investor ConferencesMay 1 at 4:05 PM | globenewswire.comSutro Biopharma (NASDAQ:STRO) Given Neutral Rating at HC WainwrightMay 1 at 8:42 AM | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from AnalystsApril 28 at 2:24 AM | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Recommendation of "Hold" by BrokeragesApril 27, 2025 | americanbankingnews.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%April 26, 2025 | aaii.comContrasting Bio-Techne (NASDAQ:TECH) and Sutro Biopharma (NASDAQ:STRO)April 26, 2025 | americanbankingnews.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%April 1, 2025 | aaii.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%March 18, 2025 | aaii.comSutro Biopharma downgraded to Neutral from Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Sutro Biopharma (STRO)March 17, 2025 | msn.comSutro Biopharma presents expanded data from REFRalphaME-01 trialMarch 17, 2025 | markets.businessinsider.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | globenewswire.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 35.19%March 15, 2025 | aaii.comWedbush Downgrades Sutro Biopharma (STRO)March 15, 2025 | msn.comSutro Biopharma downgraded to Neutral from Overweight at Piper SandlerMarch 14, 2025 | markets.businessinsider.comSutro Cuts Half of Staff, Deprioritizes ADC in Strategic ReviewMarch 14, 2025 | biospace.comNew ADC focus as Sutro slashes workforce, drops lead drugMarch 14, 2025 | thepharmaletter.comSutro drops as portfolio review leads to downgradesMarch 14, 2025 | msn.comSutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2024 Financial Results and Business HighlightsMarch 14, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Stocks Presenting Generational Buying OpportunitiesBy Chris Markoch | April 25, 2025View 3 Stocks Presenting Generational Buying OpportunitiesWith a 60%+ Upside, There’s Plenty to Love About LovesacBy Jea Yu | April 20, 2025View With a 60%+ Upside, There’s Plenty to Love About Lovesac3 Stocks With Explosive Sales Growth and Strong Cash FlowBy Leo Miller | April 14, 2025View 3 Stocks With Explosive Sales Growth and Strong Cash FlowShould You Ditch Index Funds? Why High-Yield ETFs Might Be BetterBy Dan Schmidt | April 29, 2025View Should You Ditch Index Funds? Why High-Yield ETFs Might Be BetterAmazon's Earnings Will Make or Break the Stock's Comeback By Sam Quirke | April 30, 2025View Amazon's Earnings Will Make or Break the Stock's Comeback CMMB, SAVA, MNOV, and STRO Company DescriptionsChemomab Therapeutics NASDAQ:CMMB$1.37 +0.02 (+1.48%) Closing price 03:58 PM EasternExtended Trading$1.36 -0.01 (-0.36%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.MediciNova NASDAQ:MNOV$1.47 -0.05 (-3.29%) Closing price 04:00 PM EasternExtended Trading$1.49 +0.02 (+1.36%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Cassava Sciences NASDAQ:SAVA$1.62 +0.06 (+3.85%) Closing price 04:00 PM EasternExtended Trading$1.62 0.00 (0.00%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Sutro Biopharma NASDAQ:STRO$1.07 +0.02 (+1.90%) Closing price 04:00 PM EasternExtended Trading$1.04 -0.03 (-2.34%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
